PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Category: Business
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today …
KOVR — New Edmonton-Developed VR Software Helping Diabetes Patients Now Being Tested on Ophthalmology Patients
EDMONTON, Alberta–(BUSINESS WIRE)–Local VR developer begins beta testing its new software platform, Stratos, in limited clinical testing.
First Segment of Kopin’s Three Part Webinar Series "AR and VR: The Paradigm Shift to Smartglasses Starts Now" Draws Over 300 Participants
WESTBOROUGH, Mass.–(BUSINESS WIRE)–Kopin® Corporation (NASDAQ: KOPN), a leading developer and provider of transmissive and reflective active matrix liquid crystal and organic light emitting diode (OLED) microdisplays used in military, enterprise, ind…
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announc…
NovaBay Pharmaceuticals to Hold First Quarter 2021 Conference Call on May 6
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three months ended March 31, 2021 after market close on Thursday, May 6, 2021 and will hold an investment commun…
Q-State Biosciences Presents at the 2021 Neuroimmunology Drug Development Summit
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences announces new data presented at the 2021 Neuroimmunology Drug Development Summit.
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
GENEVA–(BUSINESS WIRE)–Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
UnitedHealthcare Enhances Integration of Medical and Specialty Benefits, Helping Improve Health Outcomes and Affordability
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare has introduced various enhancements to its integrated approach to medical and specialty benefits, providing members with a more simplified experience and enabling employers to help improve employee h…
Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
GENEVA–(BUSINESS WIRE)–Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Eye Health America Continues Expanding Across the Southeast Partnering With the Eye Care Center in Upstate South Carolina
GREENVILLE, S.C.–(BUSINESS WIRE)–Today, Eye Health America (EHA), a leading eye care practice management organization in the Southeast, welcomes Drs. William Milford and Marion K. Williams of The Eye Care Center, into its business family. The Eye Car…
Biomarck’s MARCKS Inhibitors for Uveitis to be Presented at the 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
NEWTOWN, Pa.–(BUSINESS WIRE)– #cytokinestorm–Biomarck’s MARCKS inhibitors for uveitis will be presented at the 2021 Annual Meeting of Association for Research in Vision and Ophthalmology (ARVO).
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
CHMP empfiehlt EU-Zulassung von Enspryng (Satralizumab) von Chugai für Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) hat heute bekannt gegeben, dass Roche eine Mitteilung vom Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) erhalten hat, wonach dieser die Zulassung…
CHMP recommande l'approbation par l'UE de l'Enspryng (satralizumab) de Chugai pour le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé aujourd’hui que, selon une notification adressée à la société Roche, le comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments (EMA) a recomma…
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M….
Midwest Vision Partners Announces Partnership With Eye Centers of Ohio
CHICAGO & CANTON, OHIO–(BUSINESS WIRE)– #eyecare–Midwest Vision Partners Announces Partnership With Eye Centers of Ohio
CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of t…
Bollé Safety biedt nu Trivex-lenzen voor haar veiligheidsbrillen op sterkte
VILLEURBANNE, Frankrijk–(BUSINESS WIRE)–Wereldwijde oogbeschermingsspecialist Bollé Safety biedt nu Trivex aan. Een hoogwaardige, hoogtechnologische lens op sterkte die maximale veiligheid en uitstekende optische eigenschappen biedt om de beste veili…